Journal of neurosurgery. Case lessons · 2025
Intratumoral hemorrhage from brain metastases following nivolumab therapy for malignant melanoma: illustrative case.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Iinuma Takahiro, Yamada Hiroki, Kusuhara Shota, Funakoshi Shinsuke, Hirose Shigemichi, Terao Satoshi
Аннотация
BACKGROUND: Malignant melanoma is a highly aggressive type of cancer that frequently causes brain metastases, leading to poor outcomes. Immune checkpoint inhibitors (ICIs), such as nivolumab, play a crucial role in treating metastatic melanoma, yet intracranial hemorrhage (ICH) is a rare but serious complication. Although pseudoprogression and hyperprogressive disease are recognized phenomena associated with ICIs, the precise mechanisms connecting ICIs to ICH are not yet fully understood.
OBSERVATIONS: The authors report the case of a 75-year-old man with stage IV malignant melanoma who experienced an ICH 5 days after starting nivolumab monotherapy. Imaging revealed a hemorrhagic brain metastasis in the left temporal lobe, necessitating a craniotomy. Histopathology confirmed melanoma metastasis without signs of pseudoprogression or hyperprogressive disease. The patient received whole-brain radiation therapy after surgery but continued to exhibit persistent aphasia and cognitive decline deficits.
LESSONS: Early-phase intratumoral hemorrhage can occur shortly after ICI therapy, presenting diagnostic and management challenges. While this complication may result from the tumor's inherent hemorrhagic potential or ICI-induced changes such as pseudoprogression, hyperprogressive disease, or tumor lysis, its precise cause often remains unclear. Close monitoring during ICI treatment is essential to promptly address these potentially life-threatening events. https://thejns.org/doi/10.3171/CASE2581.
OBSERVATIONS: The authors report the case of a 75-year-old man with stage IV malignant melanoma who experienced an ICH 5 days after starting nivolumab monotherapy. Imaging revealed a hemorrhagic brain metastasis in the left temporal lobe, necessitating a craniotomy. Histopathology confirmed melanoma metastasis without signs of pseudoprogression or hyperprogressive disease. The patient received whole-brain radiation therapy after surgery but continued to exhibit persistent aphasia and cognitive decline deficits.
LESSONS: Early-phase intratumoral hemorrhage can occur shortly after ICI therapy, presenting diagnostic and management challenges. While this complication may result from the tumor's inherent hemorrhagic potential or ICI-induced changes such as pseudoprogression, hyperprogressive disease, or tumor lysis, its precise cause often remains unclear. Close monitoring during ICI treatment is essential to promptly address these potentially life-threatening events. https://thejns.org/doi/10.3171/CASE2581.